SMN2 copy number is an important modifier of spinal muscular atrophy (SMA), but it cannot predict one child’s future on its own. More copies generally allow more production of functional SMN protein and are associated with milder untreated disease at the group level. Age at diagnosis, symptoms already present, treatment timing and other biological factors also matter.
For a family reading a newborn-screening or diagnostic report, the first task is to understand what SMN1 and SMN2 each contribute. The next is to turn that information into a timely specialist plan. The examples below are fictional; none assigns a prognosis or selects treatment for an individual.
SMN1 establishes the usual genetic cause; SMN2 modifies it
Most 5q SMA results from disease-causing changes affecting both copies of SMN1. SMN2 is a closely related gene that can produce some full-length SMN protein, but much of its RNA is spliced in a way that omits exon 7. Copy number counts how many copies of SMN2 the laboratory detects; it is not a direct measurement of protein production in motor neurons. MedlinePlus Genetics explains SMN2’s role.
A person may have several SMN2 copies without having SMA. Conversely, the same SMN2 count can occur in people with different disease courses. The SMA GeneReviews chapter describes the genetic diagnosis and the relationship between genotype and phenotype. Do not read a copy-number row separately from the SMN1 findings and the reason the test was performed.
Why the same copy number does not mean the same outcome
Example: three copies in two infants. One infant is identified by newborn screening before weakness is apparent; another is diagnosed after symptoms develop. Both reports say three SMN2 copies. It would be misleading to tell the families that the matching count guarantees matching future motor abilities. Their starting clinical states and treatment histories differ.
Historical tables linking copy number with SMA “type” largely describe untreated disease. They help explain broad associations, but should not be turned into fixed forecasts for a child receiving modern treatment. A useful discussion includes present motor function, breathing and feeding, age at symptom onset, and the treatment and supportive-care plan.
A screen-positive result needs prompt follow-up
The 2024 best-practice recommendations on diagnosis emphasize urgent confirmatory evaluation, including SMN1 and SMN2 assessment. A screening result is an entry to that pathway, not a complete clinical assessment. Do not wait for visible weakness before contacting the screening or neuromuscular team.
The companion 2024 treatment recommendations emphasize starting appropriate treatment as early as possible after diagnosis. Eligibility, safety assessment and the choice among available approaches need current specialist advice. A higher copy count is not a reason for a family to postpone that discussion or for a website to promise that treatment is unnecessary.
What to do when laboratories report different counts
Example: “three” on one report, “four” on another. The family understandably prefers the more reassuring number. The right response is to reconcile the reports, not choose one. Ask whether both tests measured the same target, whether a range or uncertainty was reported, and whether the laboratory recommends a validated confirmatory method. Complex SMN-region structure can complicate analysis.
The diagnosis recommendations highlight the importance of accurate copy-number characterization, including distinguishing four from five copies when clinically relevant. Laboratory clarification should be coordinated with the clinical team; it should not become an open-ended delay to time-sensitive care.
| Report detail | Question to ask |
|---|---|
| SMN1 finding | What confirms the diagnosis, and are both disease-causing alleles accounted for? |
| SMN2 copy number | Is this an exact validated count, a range, or a result with limitations? |
| Method and sample | Was this screening or confirmatory testing, and does the laboratory recommend clarification? |
| Additional sequence findings | Were modifiers assessed, and what evidence supports their interpretation? |
What does the SMN2 c.859G>C modifier tell us?
The c.859G>C change can improve inclusion of exon 7 in SMN2 RNA. Prior and colleagues’ 2009 primary study described it in three unexpectedly mild cases and investigated its effect on splicing. This is an important demonstration that SMN2 copies are not necessarily functionally equivalent.
Later work on c.859G>C further examined affected individuals and the SMN region. These findings support a modifying role, but selected individuals with milder disease are not a population-wide calculator of future function. Nor does an association with untreated phenotype automatically establish which treatment will work best.
Example: a modifier on the report. A parent asks, “Does this mean my child will walk?” The evidence does not justify that promise. A more useful response distinguishes what the modifier is known to do biologically from what has been demonstrated about outcomes in comparable treated children. The finding belongs in the specialist assessment alongside the child’s examination.
For researchers: prognosis and treatment response are different claims
A study may show that a genetic feature is associated with a milder course. To claim that it predicts greater benefit from a particular treatment requires a different analysis: does the treatment effect vary by that feature, with appropriate comparison and adequate data?
Example: a small treated subgroup. A trial reports better motor scores among participants with more SMN2 copies. Before attributing the difference to a larger treatment response, compare age, baseline function, symptom duration, prior treatment and follow-up. The groups may have differed before treatment. An observational association does not isolate a treatment-by-copy-number interaction.
Use the paper-comparison worksheet to record the population, timing, endpoint and uncertainty. Report subgroup sizes and confidence intervals where available; do not translate a small subgroup average into an individual promise. The journal-club worksheet helps separate the authors’ measured results from broader interpretation.
Five questions for the next clinical conversation
- Is the SMA diagnosis confirmed, and is any laboratory uncertainty still being resolved?
- What does the examination show now, independently of the copy count?
- What are the immediate treatment and supportive-care steps?
- Which claims about modifiers are established, and which remain research questions?
- How will progress be assessed over time, and who should we contact between appointments?
Our genetic test limitations guide explains why a report’s method matters. The care finder can help organize a referral discussion, but an abnormal newborn screen should go directly through the urgent pathway provided by the screening or clinical team.